ArticleBlood cancer journal2025

Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.

Clémentine Sarkozy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.